JP2003526686A5 - - Google Patents

Download PDF

Info

Publication number
JP2003526686A5
JP2003526686A5 JP2001566747A JP2001566747A JP2003526686A5 JP 2003526686 A5 JP2003526686 A5 JP 2003526686A5 JP 2001566747 A JP2001566747 A JP 2001566747A JP 2001566747 A JP2001566747 A JP 2001566747A JP 2003526686 A5 JP2003526686 A5 JP 2003526686A5
Authority
JP
Japan
Prior art keywords
amino
phenylamino
carbonitrile
cyano
quinoline
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2001566747A
Other languages
English (en)
Japanese (ja)
Other versions
JP2003526686A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2001/007068 external-priority patent/WO2001068186A2/en
Publication of JP2003526686A publication Critical patent/JP2003526686A/ja
Publication of JP2003526686A5 publication Critical patent/JP2003526686A5/ja
Withdrawn legal-status Critical Current

Links

JP2001566747A 2000-03-13 2001-03-06 結腸ポリープの治療または阻害するためのシアノキノリンの使用 Withdrawn JP2003526686A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US52419600A 2000-03-13 2000-03-13
US09/524,196 2000-03-13
PCT/US2001/007068 WO2001068186A2 (en) 2000-03-13 2001-03-06 Use of cyanoquinolines for treating or inhibiting colonic polyps

Publications (2)

Publication Number Publication Date
JP2003526686A JP2003526686A (ja) 2003-09-09
JP2003526686A5 true JP2003526686A5 (enExample) 2008-04-24

Family

ID=24088181

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2001566747A Withdrawn JP2003526686A (ja) 2000-03-13 2001-03-06 結腸ポリープの治療または阻害するためのシアノキノリンの使用

Country Status (23)

Country Link
EP (1) EP1263503B1 (enExample)
JP (1) JP2003526686A (enExample)
KR (2) KR20080009294A (enExample)
CN (1) CN1190197C (enExample)
AR (1) AR035482A1 (enExample)
AT (1) ATE308364T1 (enExample)
AU (2) AU2001245452B2 (enExample)
BR (1) BR0109165A (enExample)
CA (1) CA2402742C (enExample)
DE (1) DE60114580T2 (enExample)
DK (1) DK1263503T3 (enExample)
EA (1) EA200200976A1 (enExample)
ES (1) ES2248302T3 (enExample)
HK (1) HK1048775B (enExample)
HU (1) HUP0300547A2 (enExample)
IL (2) IL151249A0 (enExample)
MX (1) MXPA02008836A (enExample)
NO (1) NO20024356L (enExample)
NZ (1) NZ521117A (enExample)
PL (1) PL202873B1 (enExample)
TW (1) TWI262805B (enExample)
WO (1) WO2001068186A2 (enExample)
ZA (1) ZA200208178B (enExample)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6576644B2 (en) 2000-09-06 2003-06-10 Bristol-Myers Squibb Co. Quinoline inhibitors of cGMP phosphodiesterase
US7019012B2 (en) 2000-12-20 2006-03-28 Boehringer Ingelheim International Pharma Gmbh & Co. Kg Quinazoline derivatives and pharmaceutical compositions containing them
AU2002352878B2 (en) 2001-11-27 2007-11-22 Merck Sharp & Dohme Corp. 2-Aminoquinoline compounds
EP1477481B1 (en) * 2002-01-28 2009-07-22 Ube Industries, Ltd. Process for producing quinazolin-4-one derivative
BR0307375A (pt) 2002-02-05 2004-12-07 Wyeth Corp Processo para a sìntese de ácidos n-acil-2-amino-4-alcóxi-5-nitro-benzóicos
JP2005536462A (ja) * 2002-04-30 2005-12-02 ユン ジン ファーマスーチカル インダストリーズ カンパニー リミテッド カスパーゼ−3阻害剤としてのキノリン誘導体、この製造方法及びこれを含む薬剤学的組成物
DE10221018A1 (de) 2002-05-11 2003-11-27 Boehringer Ingelheim Pharma Verwendung von Hemmern der EGFR-vermittelten Signaltransduktion zur Behandlung von gutartiger Prostatahyperplasie (BPH)/Prostatahypertrophie
CA2491191C (en) 2002-07-15 2014-02-04 Exelixis, Inc. Receptor-type kinase modulators and methods of use
US7109337B2 (en) 2002-12-20 2006-09-19 Pfizer Inc Pyrimidine derivatives for the treatment of abnormal cell growth
ATE458731T1 (de) 2002-12-20 2010-03-15 Pfizer Prod Inc Pyrimidin-derivate zur behandlung von anormalem zellwachstum
KR101218213B1 (ko) 2003-07-03 2013-01-04 시토비아 인크. 카스파제의 활성인자 및 세포자멸사의 유도인자로서의4-아릴아미노-퀴나졸린
US8309562B2 (en) 2003-07-03 2012-11-13 Myrexis, Inc. Compounds and therapeutical use thereof
CA2744997A1 (en) 2003-09-26 2005-04-07 Exelixis, Inc. C-met modulators and method of use
TW200529846A (en) 2004-02-20 2005-09-16 Wyeth Corp 3-quinolinecarbonitrile protein kinase inhibitors
NZ551027A (en) 2004-04-08 2011-01-28 Targegen Inc Benzotriazine inhibitors of kinases
EP1758887A1 (en) 2004-05-14 2007-03-07 Pfizer Products Incorporated Pyrimidine derivatives for the treatment of abnormal cell growth
CA2566332A1 (en) 2004-05-14 2005-11-24 Pfizer Products Inc. Pyrimidine derivatives for the treatment of abnormal cell growth
JP2007537235A (ja) 2004-05-14 2007-12-20 ファイザー・プロダクツ・インク 異常細胞増殖の治療用ピリミジン誘導体
CA2592900A1 (en) 2005-01-03 2006-07-13 Myriad Genetics Inc. Nitrogen containing bicyclic compounds and therapeutical use thereof
US8258145B2 (en) 2005-01-03 2012-09-04 Myrexis, Inc. Method of treating brain cancer
AU2006249596A1 (en) * 2005-05-25 2006-11-30 Wyeth Methods of synthesizing 6-alkylaminoquinoline derivatives
MY167260A (en) 2005-11-01 2018-08-14 Targegen Inc Bi-aryl meta-pyrimidine inhibitors of kinases
JP5688877B2 (ja) 2005-11-11 2015-03-25 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 癌疾患の治療用キナゾリン誘導体
DE102006029446A1 (de) * 2006-06-21 2007-12-27 Bayer Schering Pharma Ag Neue 3-substituierte-Chinoline als Kinase-Inhibitoren
DE102006029445A1 (de) * 2006-06-21 2007-12-27 Bayer Schering Pharma Ag Neue 3-Cyano-chinoline als Kinase-Inhibitoren
CA2663599A1 (en) 2006-09-18 2008-03-27 Boehringer Ingelheim International Gmbh Method for treating cancer harboring egfr mutations
DE102007024470A1 (de) 2007-05-24 2008-11-27 Bayer Schering Pharma Aktiengesellschaft Neue Sulfoximin-substituierte Chinolin- bzw. Chinazolinderivate als Kinase-Inhibitoren
EP2072502A1 (de) 2007-12-20 2009-06-24 Bayer Schering Pharma Aktiengesellschaft Sulfoximid-substituierte Chinolin- und Chinazolinderivate als Kinase-Inhibitoren
DK2387563T4 (da) 2009-01-16 2022-07-18 Exelixis Inc Malatsalt af n-(4-{ [ 6, 7-bis(methyloxy)quinolin-4-yl]oxy}phenyl-n'-(4-fluorphenyl)cyclopropan-1,1-dicarboxamid, og krystallinske former deraf til behandling af cancer
EP2445886B1 (en) 2009-06-25 2016-03-30 Amgen, Inc 4-aminoquinoline derivatives as pi3k inhibitors
JP5963672B2 (ja) 2009-07-06 2016-08-03 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Bibw2992、その塩及びこの活性成分を含む固体医薬製剤の乾燥方法
UA108618C2 (uk) 2009-08-07 2015-05-25 Застосування c-met-модуляторів в комбінації з темозоломідом та/або променевою терапією для лікування раку
AU2010363329A1 (en) 2010-11-07 2013-05-09 Targegen, Inc. Compositions and methods for treating myelofibrosis
US9227978B2 (en) 2013-03-15 2016-01-05 Araxes Pharma Llc Covalent inhibitors of Kras G12C
JO3805B1 (ar) 2013-10-10 2021-01-31 Araxes Pharma Llc مثبطات كراس جي12سي
US9242965B2 (en) 2013-12-31 2016-01-26 Boehringer Ingelheim International Gmbh Process for the manufacture of (E)-4-N,N-dialkylamino crotonic acid in HX salt form and use thereof for synthesis of EGFR tyrosine kinase inhibitors
JP6533997B2 (ja) * 2014-12-26 2019-06-26 株式会社ヤクルト本社 Znf143阻害活性を有する化合物およびその利用
EP3280708B1 (en) * 2015-04-10 2021-09-01 Araxes Pharma LLC Substituted quinazoline compounds and methods of use thereof
WO2017058728A1 (en) 2015-09-28 2017-04-06 Araxes Pharma Llc Inhibitors of kras g12c mutant proteins
US10875842B2 (en) 2015-09-28 2020-12-29 Araxes Pharma Llc Inhibitors of KRAS G12C mutant proteins
EP3356354A1 (en) 2015-09-28 2018-08-08 Araxes Pharma LLC Inhibitors of kras g12c mutant proteins
WO2017058902A1 (en) 2015-09-28 2017-04-06 Araxes Pharma Llc Inhibitors of kras g12c mutant proteins
EA038635B9 (ru) 2015-11-16 2021-10-26 Араксис Фарма Ллк 2-замещенные соединения хиназолина, содержащие замещенную гетероциклическую группу, и способы их применения
US11279689B2 (en) 2017-01-26 2022-03-22 Araxes Pharma Llc 1-(3-(6-(3-hydroxynaphthalen-1-yl)benzofuran-2-yl)azetidin-1 yl)prop-2-en-1-one derivatives and similar compounds as KRAS G12C modulators for treating cancer
US11059819B2 (en) 2017-01-26 2021-07-13 Janssen Biotech, Inc. Fused hetero-hetero bicyclic compounds and methods of use thereof
EP3573964A1 (en) 2017-01-26 2019-12-04 Araxes Pharma LLC Benzothiophene and benzothiazole compounds and methods of use thereof
WO2018140514A1 (en) 2017-01-26 2018-08-02 Araxes Pharma Llc 1-(6-(3-hydroxynaphthalen-1-yl)quinazolin-2-yl)azetidin-1-yl)prop-2-en-1-one derivatives and similar compounds as kras g12c inhibitors for the treatment of cancer
US11274093B2 (en) 2017-01-26 2022-03-15 Araxes Pharma Llc Fused bicyclic benzoheteroaromatic compounds and methods of use thereof
CN110831933A (zh) 2017-05-25 2020-02-21 亚瑞克西斯制药公司 喹唑啉衍生物作为突变kras、hras或nras的调节剂
EP3630745A2 (en) 2017-05-25 2020-04-08 Araxes Pharma LLC Covalent inhibitors of kras
JP2020521741A (ja) 2017-05-25 2020-07-27 アラクセス ファーマ エルエルシー がんの処置のための化合物およびその使用の方法
BR112021001709A2 (pt) 2018-08-01 2021-05-04 Araxes Pharma Llc compostos espiro heterocíclicos e métodos de uso dos mesmos para o tratamento de câncer

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6002008A (en) * 1997-04-03 1999-12-14 American Cyanamid Company Substituted 3-cyano quinolines
UA73073C2 (uk) * 1997-04-03 2005-06-15 Уайт Холдінгз Корпорейшн Заміщені 3-ціанохіноліни, спосіб їх одержання та фармацевтична композиція
IL147913A0 (en) * 1999-08-12 2002-08-14 American Cyanamid Co Nsaid and efgr kinase inhibitor containing composition for the treatment or inhibition of colonic polyps and colorectal cancer

Similar Documents

Publication Publication Date Title
JP2003526686A5 (enExample)
ZA200208178B (en) Use of cyanoquinolines for treating or inhibiting colonic polyps.
RU99123060A (ru) Замещенные 3-цианохинолины
RU2006106267A (ru) Применение комбинации ингибитора киназы рецептора эпидермального фактора роста и цитотоксических средств для лечения и ингибирования рака
GEP20257770B (en) Compounds for the treatment of kinase-dependent disorders
AU2001245452A1 (en) Use of cyanoquinolines for treating or inhibiting colonic polyps
RU2005113988A (ru) Стабилизированная фармацевтическая композиция, содержащая основные наполнители
UA91006C2 (ru) Способ получения аминокротонильных соединений
RU2004119438A (ru) Производные бензотиазола
JP2016512256A5 (enExample)
RU2007137266A (ru) Хиназолиноновые антагонисты кальциевых каналов т-типа
RU2007134908A (ru) Применение ингибитора активности киназы рецептора эпидермального фактора роста для лечения пациентов, невосприимчивых к гефитинибу
JP2006505530A5 (enExample)
JP2019524844A5 (enExample)
JP2018513868A5 (enExample)
RU2350618C2 (ru) ПРОИЗВОДНЫЕ ХИНАЗОЛИНА В КАЧЕСТВЕ ИНГИБИТОРОВ Src ТИРОЗИНКИНАЗЫ
US20200085814A1 (en) Combination of certinib with an egfr inhibitor
JP2006522023A5 (enExample)
RU2004127869A (ru) Новые лекарственные композиции на основе антихолинергических средств и ингибиторов egfr-киназы
WO2005120504A3 (en) Cancer treatment method
JP2013142059A (ja) 腎細胞がん治療剤
JP2005529180A5 (enExample)
Klein et al. Neratinib
Dewaele PDGF receptors as therapeutic targets in sarcomas
RU2002123886A (ru) Производные гидроксифенил-пиперазинил-метил-бензамида для лечения боли